{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:06:49Z","timestamp":1783192009667,"version":"3.54.6"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.tjog.2024.08.022","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T22:55:38Z","timestamp":1777071338000},"page":"600-601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Crizotinib for refractory vulvar malignant melanoma with equivocal MET amplification: a case report"],"prefix":"10.1016","volume":"65","author":[{"given":"Chia-Jung","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Mou","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjog.2024.08.022_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ctrv.2018.12.005","article-title":"Vulvar malignant melanoma: pathogenesis, clinical behaviour and management: review of the literature","volume":"73","author":"Boer","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.tjog.2024.08.022_bib2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4103\/2311-3006.362640","article-title":"Combined immune checkpoint inhibitors, immunotherapy with picibanil-based intraperitoneal imiquimod, and chemotherapy in cases of advanced cervical cancer and failure of concurrent chemoradiation therapy: a new clinical paradigm","volume":"9","author":"Peng","year":"2022","journal-title":"J Cancer Res Prac"},{"issue":"9","key":"10.1016\/j.tjog.2024.08.022_bib3","doi-asserted-by":"crossref","first-page":"e839","DOI":"10.1093\/oncolo\/oyad184","article-title":"Therapeutic responses to combination nivolumab and temozolomide as salvage therapy for metastatic Melanoma: a case series","volume":"28","author":"Goodman","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.tjog.2024.08.022_bib4","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2024.08.022_bib5","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/CMR.0000000000000844","article-title":"Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?","volume":"32","author":"Klee","year":"2022","journal-title":"Melanoma Res"},{"key":"10.1016\/j.tjog.2024.08.022_bib6","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1093\/oncolo\/oyab068","article-title":"Efficacy and safety of apatinib in patients with recurrent or refractory melanoma","volume":"27","author":"Yuan","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.tjog.2024.08.022_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002820","article-title":"Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver?","volume":"9","author":"Najjar","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.tjog.2024.08.022_bib8","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jtho.2021.02.010","article-title":"Crizotinib in patients with MET-amplified NSCLC","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.tjog.2024.08.022_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41591-019-0716-8","article-title":"Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration","volume":"26","author":"Drilon","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.tjog.2024.08.022_bib10","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/1535-7163.MCT-13-0499","article-title":"Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model","volume":"12","author":"Surriga","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.tjog.2024.08.022_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1149918","article-title":"The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanoma","volume":"10","author":"Sabbah","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.tjog.2024.08.022_bib12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41419-019-1875-8","article-title":"Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF\/NRAS mutation status","volume":"10","author":"Das","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.tjog.2024.08.022_bib13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12943-022-01565-1","article-title":"CRISPR\/Cas9 and next generation sequencing in the personalized treatment of cancer","volume":"21","author":"Selvakumar","year":"2022","journal-title":"Mol Cancer"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455926001142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455926001142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T22:57:58Z","timestamp":1777071478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455926001142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1028455926001142"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2024.08.022","relation":{},"ISSN":["1028-4559"],"issn-type":[{"value":"1028-4559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Crizotinib for refractory vulvar malignant melanoma with equivocal MET amplification: a case report","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2024.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}